How much funding has Nocion Therapeutics raised?

Nocion Therapeutics has raised $107.0M in total funding, most recently a series b round.

Who are Nocion Therapeutics's investors?

Nocion Therapeutics's investors include F-Prime Capital, Arkin Bio Ventures, Monograph Capital, Canaan Partners, Mass General Brigham Ventures, Mission BioCapital.

When was Nocion Therapeutics founded?

Nocion Therapeutics was founded in 2019.

Where is Nocion Therapeutics headquartered?

Nocion Therapeutics is headquartered in Watertown, Massachusetts, United States.

What industry is Nocion Therapeutics in?

Nocion Therapeutics operates in Biotech.

How many employees does Nocion Therapeutics have?

Nocion Therapeutics has 1-10 employees.

Nocion Therapeutics

Watertown, United States · Founded 2019 · $107.0M raised

Biotech

Headquarters: Watertown, Massachusetts
Employees: 1–10
Founded: 2019
Business Model: B2B

Total Funding: $107.0M
Last Round: $23.0M Series BJan 2026
Rounds: 3

About

Nocion Therapeutics is a clinical-stage biopharmaceutical company developing targeted molecules designed to calm overactive sensory nerves at their source. Its lead program, taplucainium dry powder for inhalation, is a first-in-class therapy in late-stage development for refractory or unexplained chronic cough, addressing an estimated 9 million U.S. patients with few effective options.

Summary

Nocion Therapeutics is a Biotech company based in Watertown, United States, founded in 2019. It has raised $107.0M in total across 3 rounds, most recently a $23.0M Series B round in Jan 2026. Investors include F-Prime Capital, Arkin Bio Ventures and Monograph Capital.